| Geoffrey E Starr, MD | |
|
7 Alumni Dr, Exeter, NH 03833-2118 | |
| (603) 777-1000 | |
| (603) 777-1001 |
| Full Name | Geoffrey E Starr |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 33 Years |
| Location | 7 Alumni Dr, Exeter, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831118017 | NPI | - | NPPES |
| 3087941 | Medicaid | NH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | 10259 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Androscoggin Valley Hospital | Berlin, NH | Hospital |
| Memorial Hospital, The | North conway, NH | Hospital |
| Weeks Medical Center | Lancaster, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Androscoggin Valley Hospital Inc | 2365350725 | 43 |
News Archive
A new study reports this finding, along with varying antibody prevalence among different groups and regions and between different age groups. In the current paper, available as a preprint on the medRxiv* server, the results of the sixth round of the REACT-2 study are reported.
Environmental health advocates responded to today's announcement that Food and Drug Administration concurs with the National Toxicology Program's assessment that bisphenol A is a chemical of concern. FDA posted tips for parents to minimize children's exposure, and announced further research. BPA is a synthetic sex hormone linked to cancer, behavioral changes, reproductive harm, heart problems and other illnesses.
QR Pharma, Inc., a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment and Alzheimer's disease and the Medical University of South Carolina (MUSC) announced today that they received a Small Business Innovation Research (SBIR) phase I grant in the amount of $220,000 to study Posiphen® and its metabolites in cell culture and in transgenic Alzheimer mice.
Bristol-Myers Squibb Company and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved ELIQUIS (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
In support of the Government of Canada's commitment to strengthening Canada's healthcare system, the Honourable Leona Aglukkaq, Minister of Health, announced today funding for 25 policy-relevant research projects across six provinces.
› Verified 1 days ago
| Entity Name | Androscoggin Valley Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386680593 PECOS PAC ID: 2365350725 Enrollment ID: O20040402000121 |
News Archive
A new study reports this finding, along with varying antibody prevalence among different groups and regions and between different age groups. In the current paper, available as a preprint on the medRxiv* server, the results of the sixth round of the REACT-2 study are reported.
Environmental health advocates responded to today's announcement that Food and Drug Administration concurs with the National Toxicology Program's assessment that bisphenol A is a chemical of concern. FDA posted tips for parents to minimize children's exposure, and announced further research. BPA is a synthetic sex hormone linked to cancer, behavioral changes, reproductive harm, heart problems and other illnesses.
QR Pharma, Inc., a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment and Alzheimer's disease and the Medical University of South Carolina (MUSC) announced today that they received a Small Business Innovation Research (SBIR) phase I grant in the amount of $220,000 to study Posiphen® and its metabolites in cell culture and in transgenic Alzheimer mice.
Bristol-Myers Squibb Company and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved ELIQUIS (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
In support of the Government of Canada's commitment to strengthening Canada's healthcare system, the Honourable Leona Aglukkaq, Minister of Health, announced today funding for 25 policy-relevant research projects across six provinces.
› Verified 1 days ago
| Entity Name | Androscoggin Valley Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679526644 PECOS PAC ID: 2365350725 Enrollment ID: O20040929000254 |
News Archive
A new study reports this finding, along with varying antibody prevalence among different groups and regions and between different age groups. In the current paper, available as a preprint on the medRxiv* server, the results of the sixth round of the REACT-2 study are reported.
Environmental health advocates responded to today's announcement that Food and Drug Administration concurs with the National Toxicology Program's assessment that bisphenol A is a chemical of concern. FDA posted tips for parents to minimize children's exposure, and announced further research. BPA is a synthetic sex hormone linked to cancer, behavioral changes, reproductive harm, heart problems and other illnesses.
QR Pharma, Inc., a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment and Alzheimer's disease and the Medical University of South Carolina (MUSC) announced today that they received a Small Business Innovation Research (SBIR) phase I grant in the amount of $220,000 to study Posiphen® and its metabolites in cell culture and in transgenic Alzheimer mice.
Bristol-Myers Squibb Company and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved ELIQUIS (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
In support of the Government of Canada's commitment to strengthening Canada's healthcare system, the Honourable Leona Aglukkaq, Minister of Health, announced today funding for 25 policy-relevant research projects across six provinces.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Geoffrey E Starr, MD 7 Holland Way Fl 1, Exeter, NH 03833-2997 Ph: (603) 658-8998 | Geoffrey E Starr, MD 7 Alumni Dr, Exeter, NH 03833-2118 Ph: (603) 777-1000 |
News Archive
A new study reports this finding, along with varying antibody prevalence among different groups and regions and between different age groups. In the current paper, available as a preprint on the medRxiv* server, the results of the sixth round of the REACT-2 study are reported.
Environmental health advocates responded to today's announcement that Food and Drug Administration concurs with the National Toxicology Program's assessment that bisphenol A is a chemical of concern. FDA posted tips for parents to minimize children's exposure, and announced further research. BPA is a synthetic sex hormone linked to cancer, behavioral changes, reproductive harm, heart problems and other illnesses.
QR Pharma, Inc., a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment and Alzheimer's disease and the Medical University of South Carolina (MUSC) announced today that they received a Small Business Innovation Research (SBIR) phase I grant in the amount of $220,000 to study Posiphen® and its metabolites in cell culture and in transgenic Alzheimer mice.
Bristol-Myers Squibb Company and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved ELIQUIS (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
In support of the Government of Canada's commitment to strengthening Canada's healthcare system, the Honourable Leona Aglukkaq, Minister of Health, announced today funding for 25 policy-relevant research projects across six provinces.
› Verified 1 days ago
Dr. Erika Freese Wilson, M.D./M.P.H. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 24 Front St Unit 100, Exeter, NH 03833 Phone: 603-778-2005 | |
Andrew Kaplan, DO Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 24 Front St Ste 100, Exeter, NH 03833 Phone: 603-883-0005 Fax: 603-883-0007 | |
Dr. Sarah E Slocum, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 5 Alumni Dr, Exeter, NH 03833 Phone: 603-580-7525 Fax: 603-580-7542 | |
Dr. Paul Frederick Belliveau, M.D. Psychiatry & Neurology Medicare: May Accept Medicare Assignments Practice Location: 9 Hampton Rd Ste 2, Exeter, NH 03833 Phone: 602-778-0505 Fax: 603-772-6761 | |
Dr. Robert F Donnell, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 7 Alumni Dr, Exeter, NH 03833 Phone: 603-777-1000 Fax: 603-777-1001 | |
Steven C Henricks, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 24 Front Street, #307, Exeter, NH 03833 Phone: 603-658-1777 Fax: 603-658-1333 | |
Cheryl Baggeroer, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 24 Front St, Exeter, NH 03833 Phone: 603-778-0505 Fax: 603-772-6761 |